- Home
- OUST vs GYRE Comparison
OUST vs GYRE Comparison
Compare OUST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- GYRE
- Stock Information
- Founded
- OUST 2015
- GYRE 2002
- Country
- OUST United States
- GYRE United States
- Employees
- OUST N/A
- GYRE N/A
- Industry
- OUST Industrial Machinery/Components
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OUST Technology
- GYRE Health Care
- Exchange
- OUST Nasdaq
- GYRE Nasdaq
- Market Cap
- OUST 1.1B
- GYRE 897.1M
- IPO Year
- OUST N/A
- GYRE N/A
- Fundamental
- Price
- OUST $23.38
- GYRE $7.05
- Analyst Decision
- OUST Strong Buy
- GYRE
- Analyst Count
- OUST 7
- GYRE 0
- Target Price
- OUST $17.33
- GYRE N/A
- AVG Volume (30 Days)
- OUST 2.8M
- GYRE 78.6K
- Earning Date
- OUST 08-07-2025
- GYRE 08-12-2025
- Dividend Yield
- OUST N/A
- GYRE N/A
- EPS Growth
- OUST N/A
- GYRE N/A
- EPS
- OUST N/A
- GYRE 0.02
- Revenue
- OUST $117,789,000.00
- GYRE $100,643,000.00
- Revenue This Year
- OUST $32.34
- GYRE $21.04
- Revenue Next Year
- OUST $36.11
- GYRE $89.64
- P/E Ratio
- OUST N/A
- GYRE $90.64
- Revenue Growth
- OUST 28.04
- GYRE N/A
- 52 Week Low
- OUST $5.84
- GYRE $6.11
- 52 Week High
- OUST $31.77
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- OUST 47.51
- GYRE 41.32
- Support Level
- OUST $22.07
- GYRE $7.09
- Resistance Level
- OUST $28.73
- GYRE $7.89
- Average True Range (ATR)
- OUST 2.33
- GYRE 0.37
- MACD
- OUST -0.94
- GYRE 0.02
- Stochastic Oscillator
- OUST 13.51
- GYRE 12.50
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.